Then and Now: Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), a Historical Perspective

Overview

Journal J Gastrointest Oncol

Date 2016 Mar 5

PMID 26941981

Citations 45

Authors

Madalyn G Neuwirth

H Richard Alexander

Giorgos C Karakousis

Affiliations

Soon will be listed here.

Abstract

The management of peritoneal carcinomatosis, once considered a condition with few therapeutic options, has undergone dramatic change with the advancement of surgical techniques and systemic cancer therapy. Cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) administration, in particular, has significantly impacted the prospect of improving outcomes for this debilitating presentation of malignancy in selected patients. This regional surgical therapy itself has undergone many stages of evolution through its original conception nearly a century ago. Progressive changes in this field have included refinements and ongoing standardization in technique, development of a common language to describe tumor burden and extent of resection, better selection of chemotherapeutics based on tumor histology, reduction of surgical morbidity and mortality, and an improved understanding of factors for appropriate patient selection, to list but a few examples. CRS/HIPEC continues to play an important role in the management of select patients with carcinomatosis of certain tumor histology and its role will no doubt continue to be redefined as new therapies emerge.

Citing Articles

Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy applications in upper and lower gastrointestinal cancer, a review.

Drittone D, Schipilliti F, Arrivi G, Mazzuca F Oncol Rev. 2024; 18:1496141.

PMID: 39659741 PMC: 11628282. DOI: 10.3389/or.2024.1496141.

Right Hemicolectomy and Appendicectomy as Treatments for Goblet Cell Adenocarcinoma: A Comparative Analysis of Two Large National Databases.

Asmar M, Mortagy M, Chandrakumaran K, Cecil T, Ramage J Curr Oncol. 2024; 31(7):3855-3869.

PMID: 39057157 PMC: 11276507. DOI: 10.3390/curroncol31070285.

Local anaesthetics and chemotherapeutic agents: a systematic review of preclinical evidence of interactions and cancer biology.

Abdelaatti A, Buggy D, Wall T BJA Open. 2024; 10:100284.

PMID: 38741694 PMC: 11089318. DOI: 10.1016/j.bjao.2024.100284.

Successful Implementation of HITOC and HIPEC in the Management of Advanced Ovarian Carcinoma with Pleural and Peritoneal Carcinomatosis.

Moldovan B, Saon C, Adam I, Pisica R, Silaghi V, Untaru V Diagnostics (Basel). 2024; 14(5).

PMID: 38472928 PMC: 10931012. DOI: 10.3390/diagnostics14050455.

Hyperthermic intrapleural chemotherapy: an update.

Campany M, Reck Dos Santos P, Donato B, Alwardt C, Ernani V, DCunha J J Thorac Dis. 2023; 15(9):5064-5073.

PMID: 37868886 PMC: 10586986. DOI: 10.21037/jtd-23-454.

References

Bruckner H, Cohen C, Goldberg J, KABAKOW B, Wallach R, Deppe G . Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycin. Cancer. 1981; 47(9):2288-94. DOI: 10.1002/1097-0142(19810501)47:9<2288::aid-cncr2820470931>3.0.co;2-3. View

Sugarbaker P . An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution. J Surg Oncol. 2005; 92(2):142-6. DOI: 10.1002/jso.20370. View

Boutros C, Somasundar P, Espat N . Early results on the use of biomaterials as adjuvant to abdominal wall closure following cytoreduction and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2010; 8:72. PMC: 2931502. DOI: 10.1186/1477-7819-8-72. View

Harmon R, Sugarbaker P . Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005; 2(1):3. PMC: 549516. DOI: 10.1186/1477-7800-2-3. View

Dembo A, Bush R, Beale F, Bean H, PRINGLE J, Sturgeon J . Ovarian carcinoma: improved survival following abdominopelvic irradiation in patients with a completed pelvic operation. Am J Obstet Gynecol. 1979; 134(7):793-800. View

Fujimura T, Yonemura Y, Muraoka K, Takamura H, Hirono Y, Sahara H . Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg. 1994; 18(1):150-5. DOI: 10.1007/BF00348209. View

Sugarbaker P, Gianola F, Speyer J, Wesley R, Barofsky I, Myers C . Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Semin Oncol. 1985; 12(3 Suppl 4):101-11. View

Glehen O, Cotte E, Kusamura S, Deraco M, Baratti D, Passot G . Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol. 2008; 98(4):242-6. DOI: 10.1002/jso.21061. View

Roviello F, Caruso S, Marrelli D, Pedrazzani C, Neri A, De Stefano A . Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments. Surg Oncol. 2010; 20(1):e38-54. DOI: 10.1016/j.suronc.2010.09.002. View

10.

Toi M, Shiramizu T, YONEMURA T, Ezaki T, Oka N, Yoshida T . [Intraperitoneal cisplatin in peritoneal carcinomatosis patients]. Gan No Rinsho. 1985; 31(5):522-6. View

11.

Yang X, Huang C, Suo T, Mei L, Yang G, Cheng F . Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011; 18(6):1575-81. PMC: 3087875. DOI: 10.1245/s10434-011-1631-5. View

12.

Dedrick R, Myers C, Bungay P, Devita Jr V . Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978; 62(1):1-11. View

13.

Klaver C, Musters G, Bemelman W, Punt C, Verwaal V, Dijkgraaf M . Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015; 15:428. PMC: 4492087. DOI: 10.1186/s12885-015-1430-7. View

14.

Glehen O, Kwiatkowski F, Sugarbaker P, Elias D, Levine E, de Simone M . Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004; 22(16):3284-92. DOI: 10.1200/JCO.2004.10.012. View

15.

Rossi C, Pilati P, Mocellin S, Foletto M, Ori C, Innocente F . Hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from gastric adenocarcinoma. Suppl Tumori. 2003; 2(5):S54-7. View

16.

Larkin J, Edwards W, Smith D, Clark P . Systemic thermotherapy: description of a method and physiologic tolerance in clinical subjects. Cancer. 1977; 40(6):3155-9. DOI: 10.1002/1097-0142(197712)40:6<3155::aid-cncr2820400660>3.0.co;2-e. View

17.

Verwaal V, Bruin S, Boot H, van Slooten G, van Tinteren H . 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008; 15(9):2426-32. DOI: 10.1245/s10434-008-9966-2. View

18.

Elias D, Antoun S, Goharin A, Otmany A, Puizillout J, Lasser P . Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig. 2001; 1(5):431-9. View

19.

Fujimoto S, Shrestha R, Kokubun M, Ohta M, Takahashi M, Kobayashi K . Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg. 1988; 208(1):36-41. PMC: 1493580. DOI: 10.1097/00000658-198807000-00005. View

20.

Sugarbaker P . Peritonectomy procedures. Ann Surg. 1995; 221(1):29-42. PMC: 1234492. DOI: 10.1097/00000658-199501000-00004. View